Navigation Links
AlphaVax Announces New CMV Advisory Board
Date:1/30/2008

RESEARCH TRIANGLE PARK, N.C., Jan. 30 /PRNewswire/ -- AlphaVax has assembled its Cytomegalovirus (CMV) Advisory Board to provide expertise and advice as the company moves its CMV vaccine candidates through clinical development. To be chaired by Dr. Robert Olmsted, AlphaVax's Vice President for Research, the Board members include:

-- Mark Schleiss, MD, Professor, Associate Head for Research and the

American Legion Chair in the Department of Pediatrics and Director,

Division of Infectious Diseases, at the University of Minnesota.

-- David Bernstein, MD, Albert Sabin Professor of Pediatrics, Director,

Infectious Diseases and Director of the Gamble Program at the

Cincinnati Children's Hospital and Medical Center.

-- Robert Pass, MD, Professor, Pediatrics and Microbiology at the

University of Alabama - Birmingham.

-- Paul D. Griffiths, MD, DSc, Professor and Head of the Centre for

Virology, Division of Infection at Royal Free and University College

Medical School in London.

AlphaVax is pleased to have these distinguished researchers and clinicians in the field of cytomegalovirus provide their perspectives on advancing an alphavirus vectored CMV vaccine. "We look forward to working with our CMV Advisory Board to help design and implement post-Phase I clinical programs for assessing the potential of our CMV vaccine candidates in transplant indications, prevention of mother-to-child transmission, and prophylactic adolescent immunization," said Dr. Olmsted.

About AlphaVax

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a novel alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. In addition to programs in influenza and cytomegalovirus, important disease targets include cancer, HIV and a number of biodefense vaccine products. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP manufacturing facility is located in Lenoir, NC. The company employs staff with expertise spanning vaccine design, process development, GMP manufacturing, quality assurance, and regulatory and clinical affairs.


'/>"/>
SOURCE AlphaVax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. mNEMOSCIENCE GmbH Announces Global Licensing Agreement With Aporo Biomedical
2. ADVENTRX Announces Consolidation of Clinical and Management Positions
3. Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System
4. Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast
5. BD Announces Results of Shareholder Votes at Annual Meeting
6. BioMed Realty Trust Announces Tax Treatment of 2007 Distributions
7. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
8. Sunnylife Global Announces Completion of Surgical Wing of Xiang Tan World Friendship Hospital
9. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
10. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
11. Access Pharmaceuticals Announces $2.7 Million New Equity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
Breaking Biology News(10 mins):